- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07947290
Effects of PosBion® Supplementation on Intestinal Barrier Function in Adults With Irritable Bowel Syndrome
Effects of PosBion® Supplementation on Barrier-Related Biomarkers in Adults With Irritable Bowel Syndrome
Postbiotic metabolites produced by beneficial bacteria may influence inflammatory responses, mucosal immunity, and host physiological signalling. PosBion® contains the proprietary cell-free metabolite preparations LPM5 and LPM11, derived from Lactiplantibacillus plantarum RS5 and RI11, respectively.
This study will evaluate changes in a panel of salivary biomarkers following 12 weeks of PosBion® supplementation in adults with irritable bowel syndrome (IBS). The biomarkers include myeloperoxidase (MPO), zonulin, lipopolysaccharide (LPS), LPS-binding protein (LBP), cortisol, serotonin, secretory immunoglobulin A (sIgA), lactoferrin, interleukin-8 (IL-8), immunoglobulin E (IgE), immunoglobulin M (IgM), and immunoglobulin G (IgG).
The study will primarily evaluate changes in inflammatory activity, while additional biomarkers will be used to explore mucosal immune, neuroendocrine, immunoglobulin, microbial exposure, and barrier-related responses following supplementation.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Irritable bowel syndrome is a disorder of gut-brain interaction associated with complex alterations in immune activity, gastrointestinal physiology, microbial-host interactions, and mucosal function. Microbial metabolites derived from beneficial bacteria have received increasing attention because of their potential immunomodulatory, anti-inflammatory, antioxidant, and mucosal effects.
PosBion® is a commercially available dietary supplement containing LPM5 and LPM11, proprietary cell-free metabolite preparations derived from Lactiplantibacillus plantarum RS5 and RI11, respectively. The finished preparations do not contain viable or inactivated bacterial cells.
Previous experimental investigations of RS5- and RI11-derived metabolites have demonstrated antimicrobial, antioxidant, immunomodulatory, and intestinal health-related activities. In particular, RI11-derived metabolites have been associated experimentally with modulation of inflammatory cytokines, antioxidant defence, and barrier-associated pathways.
The present study is designed as a prospective, single-arm, open-label interventional study to investigate longitudinal changes in salivary biomarkers following 12 weeks of PosBion® supplementation.
The principal biomarker of interest will be salivary IL-8 as a marker of inflammatory activity. Additional inflammatory markers will include MPO and lactoferrin. Mucosal and adaptive immune responses will be evaluated using sIgA, IgE, IgM, and IgG. Cortisol and serotonin will be investigated as neuroendocrine biomarkers.
Salivary zonulin, LPS, and LBP will also be assessed as exploratory biomarkers potentially related to microbial exposure and barrier-associated processes. Because these biomarkers are measured in saliva, they will not be interpreted as direct measurements of intestinal permeability.
Unstimulated saliva will be collected at baseline and after 4, 8, and 12 weeks of supplementation under standardized collection conditions. Biomarker concentrations will be quantified using commercially available validated assays according to the manufacturers' instructions.
The study is intended to provide mechanistic biomarker data on the biological responses associated with PosBion® supplementation rather than to evaluate changes in IBS symptom severity.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Chung Keat Tan, PhD
- Telefonnummer: +60175063305
- E-post: cktan.jsci@gmail.com
Studiesteder
-
-
Kuala Lumpur
-
Cheras, Kuala Lumpur, Malaysia, 56000
- UCSI University
-
Ta kontakt med:
- Sin Sing Eugenie Tan, PhD
- Telefonnummer: +60168924008
- E-post: eugenietan@ucsiuniversity.edu.my
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Adults aged 18 years or older
- Experienced one or more symptoms suggestive of irritable bowel syndrome (IBS) prior to enrolment
- Willing to comply with interventional plan
- Willing to give consent
Exclusion Criteria:
- History of chronic or serious medical conditions, including diabetes mellitus, cardiovascular disease, chronic kidney disease, cancer, or chronic respiratory disease
- Current use of gastrointestinal health supplements
- Current use of antibiotics or antiviral medications
- Current use of probiotic, prebiotic, or postbiotic supplements
- Major surgery within the previous 6 months.
- Pregnant or lactating woman
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: PosBion® Supplementation
Subjects will consume PosBion® for 12 consecutive weeks. Two sachets will be consumed daily, with one sachet taken after breakfast and one sachet after dinner. Saliva samples will be collected at baseline and Weeks 4, 8, and 12 for biomarker analysis. |
PosBion® contains the proprietary cell-free metabolite preparations LPM5 and LPM11 derived from Lactiplantibacillus plantarum RS5 and RI11, respectively. Each sachet contains 2,500 mg LPM5 and 2,500 mg LPM11. Subjects will consume two sachets daily for 12 weeks, with one sachet taken after breakfast and one after dinner. The finished preparations do not contain viable or inactivated bacterial cells.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Salivary Interleukin-8 (IL-8) Concentration
Tidsramme: Baseline, Week 4, Week 8, and Week 12; primary comparison: baseline to Week 12
|
Salivary IL-8 concentration will be quantified using an enzyme-linked immunosorbent assay (ELISA). Changes over time will be evaluated, with the principal comparison between baseline and Week 12. |
Baseline, Week 4, Week 8, and Week 12; primary comparison: baseline to Week 12
|
|
Change in Salivary Myeloperoxidase (MPO)
Tidsramme: Baseline, Week 4, Week 8, and Week 12
|
Salivary MPO concentration will be quantified using ELISA as a marker associated with neutrophil and inflammatory activity. |
Baseline, Week 4, Week 8, and Week 12
|
|
Change in Salivary Lactoferrin
Tidsramme: Baseline, Week 4, Week 8, and Week 12
|
Salivary lactoferrin concentration will be quantified using ELISA as a marker associated with mucosal innate immune and inflammatory activity. |
Baseline, Week 4, Week 8, and Week 12
|
|
Change in Salivary Secretory Immunoglobulin A (sIgA)
Tidsramme: Baseline, Week 4, Week 8, and Week 12
|
Salivary sIgA concentration will be quantified as a marker of mucosal immune activity. |
Baseline, Week 4, Week 8, and Week 12
|
|
Change in Salivary IgE
Tidsramme: Baseline, Week 4, Week 8, and Week 12
|
Salivary IgE concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation. |
Baseline, Week 4, Week 8, and Week 12
|
|
Change in Salivary IgM
Tidsramme: Baseline, Week 4, Week 8, and Week 12
|
Salivary IgM concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation. |
Baseline, Week 4, Week 8, and Week 12
|
|
Change in Salivary IgG
Tidsramme: Baseline, Week 4, Week 8, and Week 12
|
Salivary IgG concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation. |
Baseline, Week 4, Week 8, and Week 12
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Baseline, Week 4, Week 8, and Week 12
Tidsramme: Baseline, Week 4, Week 8, and Week 12
|
Salivary cortisol concentration will be quantified as a neuroendocrine biomarker associated with physiological stress responses. |
Baseline, Week 4, Week 8, and Week 12
|
|
Change in Salivary Serotonin
Tidsramme: Baseline, Week 4, Week 8, and Week 12
|
Salivary serotonin concentration will be quantified as an exploratory neuroendocrine biomarker. |
Baseline, Week 4, Week 8, and Week 12
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Salivary Zonulin
Tidsramme: Baseline, Week 4, Week 8, and Week 12
|
Salivary zonulin will be quantified as an exploratory biomarker potentially associated with barrier-related processes. The measurement will not be considered a direct assessment of intestinal permeability. |
Baseline, Week 4, Week 8, and Week 12
|
|
Change in Salivary Lipopolysaccharide (LPS)
Tidsramme: Baseline, Week 4, Week 8, and Week 12
|
Salivary LPS concentration will be evaluated as an exploratory marker of microbial exposure. Changes will not be interpreted as direct evidence of intestinal microbial translocation. |
Baseline, Week 4, Week 8, and Week 12
|
|
Change in Salivary LPS-Binding Protein (LBP)
Tidsramme: Baseline, Week 4, Week 8, and Week 12
|
Salivary LBP concentration will be evaluated as an exploratory biomarker related to host responses to microbial products. |
Baseline, Week 4, Week 8, and Week 12
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- POSTBION-LEAKY GUT
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
De-identified individual-level data underlying the reported study findings, together with relevant data dictionaries, may be made available to qualified researchers following publication.
IPD-delingstidsramme
Beginning approximately 6 months after publication of the primary study findings and available for up to 5 years.
Tilgangskriterier for IPD-deling
Data may be provided to qualified researchers who submit a scientifically sound proposal. Requests will be reviewed by the principal investigator and/or study sponsor. Approved access may require a data-use agreement and secure transfer of de-identified data.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .